Last week, Merck acquired OncoEthix at a price of $375 MM for OTX015, a synthetic small molecule which targets the BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). Continue reading

Last week, Merck acquired OncoEthix at a price of $375 MM for OTX015, a synthetic small molecule which targets the BET bromodomain proteins 2, 3, and 4 (BRD2/3/4). Continue reading
HDAC inhibitors work by blocking Histone De-ACetylase enzyme, which removes acetyl groups from the proteins that encase DNA, that is histones. They are triggered by CpG sequences on DNA promoters; HDACs put chromatin in a configuration that favors LACK of transcription. So, blocking HDACs favors transcription – see prior post. Continue reading